SPRO - スマ―トプロス (Spero Therapeutics Inc.) スマ―トプロス

 SPROのチャート


 SPROの企業情報

symbol SPRO
会社名 SmartPros Ltd (スマ―トプロス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   工業(Industrials)
概要 事業概要 スペル・セラピューティックス(Spero Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社は、MDR細菌感染の新規治療法の特定・開発・商業化に従事する。同社は、SPR994、増強剤プラットフォーム(SPR741とSPR206)、およびSPR720を含む新規製品候補のポートフォリオを開発している。SPR994はカルバペネム級の抗生物質であるテビペネムの新規経口製剤である。SPR994はMDR細菌感染に対して有効であり、その初期の焦点はcUTIの治療にある。ポテンシエータープラットフォームは、グラム陰性細菌に対する不活性抗生物質を含む既存の抗生物質のスペクトルおよび効力を拡大する薬物を開発することを可能にする。SPR720は、HIVを含む免疫系が損なわれた患者、または嚢胞性線維症、喘息及び気管支拡張症などの呼吸器疾患を有する患者にしばしば起こる、まれな肺感染であるNTMの治療のために設計された新規経口療法製品候補である。   スマ―トプロスは米国の教育サ―ビス会社。会計、金融サ―ビス、法務、エンジニアリング、証券、保険など、特定の市場を対象に教育・研修ソリュ―ションを提供。コ―スは、テキスト、ビデオ対話型、ライブ、オンラインセミナ―で利用できる。主な顧客は、大手企業及び、専門分野の会社や団体など。本社はニューヨーク州。   Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
本社所在地 12 Skyline Drive Hawthorne NY 10532 USA
代表者氏名 Milind S. Deshpande Milind S. Deshpande
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-242-1600
設立年月日 29677
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数 57人
url www.smartpros.com
nasdaq_url https://www.nasdaq.com/symbol/spro
adr_tso
EBITDA EBITDA(百万ドル) -44.37100
終値(lastsale) 10.44
時価総額(marketcap) 189678398.76
時価総額 時価総額(百万ドル) 183.13780
売上高 売上高(百万ドル) 3.20600
企業価値(EV) 企業価値(EV)(百万ドル) 116.50080
当期純利益 当期純利益(百万ドル) -47.44600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Spero Therapeutics Inc revenues increased from $389K to $1.6M. Net loss applicable to common stockholders increased 7% to $20.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 18% to $15.8M (expense).

 SPROのテクニカル分析


 SPROのニュース

   Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below Two Hundred Day Moving Average of $15.95  2021/12/14 08:30:42 Dakota Financial News
Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.95 and traded as low as $13.27. Spero Therapeutics shares last traded at $13.65, with a volume of 107,572 shares trading hands. Several brokerages have recently issued reports on SPRO. […]
   California State Teachers Retirement System Grows Position in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/30 09:32:44 Dakota Financial News
California State Teachers Retirement System grew its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 8.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,446 shares of the companys stock after purchasing an additional 2,523 shares during the period. California State []
   Spero Therapeutics to Present at Upcoming Investor Conferences  2021/11/17 13:05:00 Intrado Digital Media
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference and the 4 th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.
   Vanguard Group Inc. Boosts Stock Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/13 09:30:41 Dakota Financial News
Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 15.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,276,790 shares of the companys stock after purchasing an additional 170,094 shares during the period. Vanguard Group Inc.s []
   Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript  2021/11/11 03:15:03 Seeking Alpha
   Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below Two Hundred Day Moving Average of $15.95  2021/12/14 08:30:42 Dakota Financial News
Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.95 and traded as low as $13.27. Spero Therapeutics shares last traded at $13.65, with a volume of 107,572 shares trading hands. Several brokerages have recently issued reports on SPRO. […]
   California State Teachers Retirement System Grows Position in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/30 09:32:44 Dakota Financial News
California State Teachers Retirement System grew its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 8.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,446 shares of the companys stock after purchasing an additional 2,523 shares during the period. California State []
   Spero Therapeutics to Present at Upcoming Investor Conferences  2021/11/17 13:05:00 Intrado Digital Media
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference and the 4 th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.
   Vanguard Group Inc. Boosts Stock Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/13 09:30:41 Dakota Financial News
Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 15.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,276,790 shares of the companys stock after purchasing an additional 170,094 shares during the period. Vanguard Group Inc.s []
   Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript  2021/11/11 03:15:03 Seeking Alpha
   California State Teachers Retirement System Grows Position in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/30 09:32:44 Dakota Financial News
California State Teachers Retirement System grew its stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 8.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,446 shares of the companys stock after purchasing an additional 2,523 shares during the period. California State []
   Spero Therapeutics to Present at Upcoming Investor Conferences  2021/11/17 13:05:00 Intrado Digital Media
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference and the 4 th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows.
   Vanguard Group Inc. Boosts Stock Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO)  2021/11/13 09:30:41 Dakota Financial News
Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 15.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,276,790 shares of the companys stock after purchasing an additional 170,094 shares during the period. Vanguard Group Inc.s []
   Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript  2021/11/11 03:15:03 Seeking Alpha
   Spero Therapeutics EPS misses by $0.04, misses on revenue  2021/11/10 21:27:03 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 スマ―トプロス SPRO Spero Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)